DRTS
Alpha Tau Medical Ltd.
Alpha Tau Medical (DRTS) Q2 2026 earnings
Published Aug 10, 2026
AI summary
- GAAP EPS −$0.76, down from −$0.25 a year ago.
- Alpha Tau Medical reported a net loss of $68.8 million for the first half of 2026.
- The company's net loss per share was $0.76 for the six-month period ending June 30, 2026.
- Operating expenses increased as the company continued its clinical development and research activities.
- The company held $104.8 million in cash, cash equivalents, and deposits as of June 30, 2026.
Results vs analyst consensus
Revenue
Not reported in this release.
EPS · GAAP
Reported · GAAP diluted EPS
−$0.76
Consensus basis not comparable
Prior year: −$0.25
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company expects to continue incurring substantial losses during its clinical development phase.
- Financial results were significantly impacted by a $42.2 million non-cash expense from the remeasurement of warrants.
- The company's ability to reach profitability remains dependent on future regulatory approvals and financing.
Read original report
Source: Alpha Tau Medical Ltd. press release · SEC Form 6-K exhibit 99.1